Basic Information
Cuprior
Regulatory Information
EMEA/H/C/004005
Authorised
September 5, 2017
April 21, 2017
8
March 26, 2024
Company Information
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ? 5 years intolerant to D-penicillamine therapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Cuprior. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cuprior. For practical information about using Cuprior, patients should read the package leaflet or contact their doctor or pharmacist.